Self-associated submicron IgG1 particles for pulmonary delivery: Effects of non-ionic surfactants on size, shape, stability, and aerosol performance

AAPS PharmSciTech

Volumn 14, Issue 1, 2013, Pages 200-210

  Srinivasan, Asha R ^a   Shoyele, Sunday A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

aerosols; monoclonal antibodies; non ionic surfactants; pulmonary delivery; submicron particles

Indexed keywords

IMMUNOGLOBULIN G1; NANOPARTICLE; NONIONIC SURFACTANT;

AEROSOL; ARTICLE; DRUG DELIVERY SYSTEM; INHALER; ISOELECTRIC POINT; LIGHT SCATTERING; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

AEROSOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN G; LUNG; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; SPECTROPHOTOMETRY, ULTRAVIOLET; SURFACE-ACTIVE AGENTS;

EID: 84878523558     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9913-1     Document Type: Article

References (40)

1. Kegan L, Turner MR, Balu-lyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection and Injection volume on Rituximab pharmacokinetics in rats. Pharm Res. 2011. doi 10.1007/s11095-011- 0578-3.
2. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 2004;61:108-20.
3. Patton JS. Deep lung delivery of therapeutic protein. Chemtech. 1997;27:34-8.
4. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009-29.
5. Shoyele SA, Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm. 2006;314:1-8.
6. Mansour HM, Rhee Y-S, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299-319.
7. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25:563-70.
8. Bailey MM, Berkland CJ. Nanoparticles formulation in pulmonary drug delivery. Med Res Rev. 2009;29:196-212.
9. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutics nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310-6.
10. Peterson LK, Sackett CK, Narasimhan B. High throughput analysis of protein stability in polyanhydride nanoparticles. Acta Biomater. 2010;6:3873-81.
11. Kim KR, Ahn KY, Park JS, Lee KE, Jeon H, Lee J. Lyophilization and enhanced stability of fluorescent protein nanoparticles. Biochem Biophys Res Commun. 2011;408:225-9.
12. Son S, Lee WR, Joung YK, Kwom MK, Kim YS, Park KD. Optimized stability retention of a monoclonal antibody in PLGA nanoparticles. Int J Pharm. 2009;368:178-85.
13. Zhang K, Fang H, Chen Z, Taylor J-SA, Wooley KL. Shape effects of nanoparticles conjugated with cell-penetration peptides (HIV Tat PTD) on CHO cell uptake. Bioconjug Chem. 2008;19:1880-7.
14. Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T. Nano-carriers for DNA delivery to the lung based upon a TAT derived peptide covalently coupled to PEG-PEI. J Control Release. 2005;109:299-316.
15. Ingham KC. Precipitation of proteins with polyethylene glycol. In: Deutscher MP, editor. Guide to protein purification. San Diego: Academic; 1990. p. 301-6.
16. Ries-Kautt M, Ducruix A. Phase diagrams. In: Ducruix A, Giege R, editors. Cerystallization of nucleic acids and proteins. 1st ed. Oxford: Oxford University Press; 1992. p. 195-218.
17. Tummala NR, Alberto S. SDS surfactants on carbon nanotubes: aggregates morphology. ACS Nano. 2009;3:595-602.
18. Suttipon M, Tummala NR, Kitiyanan B, Alberto S. Role of surfactant molecular structure on self-assembly: aqueous SDBS on carbon nanotubes. J Phys Chem C. 2011;115:17286-96.
19. United States Pharmacopoeia (USP), United States Pharmacopoeia Convention Inc., USA, 2008.
20. Shoyele SA, Sivadas N, Cryan S-A. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation. AAPS PharmSciTech. 2011;12:304-11.
21. Dani B, Platz R, Tzannis ST. High concentration formulation feasibility of human immunoglobulin G for subcutaneous administration. J Pharm Sci. 2007;96:1504-17.
22. Hawe A, Kasper JC, Fries W, Jiskoot W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci. 2009;38:79-87.
23. Doi E, Jirgensons B. Circular dichroism studies on the acid denaturation of gamma-immunoglobulin G and its fragments. Biochemistry. 1970;9:1066-72.
24. Pelton JT, McClean LR. Spectroscopic methods for analysis of protein secondary structure. Anal Biochem. 2000;277:167-76.
25. Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF, Randolph TW. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci. 1998;87:1554-9.
26. Andya JD, Maa YF, Costantino HR, Nguyen PA, Dasovich N, Sweeney TD. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res. 1999;16:350-8.
27. Hillgren A, Alden MA. A comparison between the protection of LDH during freeze thawing by PEG 6000 and Brij 35 at low concentrations. Int J Pharm. 2002;244:137-49.
28. Sivadasan K, Somasundaran P. Polymer-surfactant interactions and the association behavior of hydrophobically modified hydroxyethylcellulose. Colloids Surf. 1990;49:229-39.
29. Liv CG, Desai KGH, Chen XG, Park HJ. Linolenic acid-modified chitosan for formation of self-assembled nanoparticles. J Agric Food Chem. 2005;53:437-41.
30. Hall JB, Dobrovolskia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Futur Med Nanomedicine. 2007;2(6):789-803.
31. Sviridov OV, Ermolenko MN, Cheikina AV, Martsev SP. Effect of structural changes in thyroxine-binding globulin on its biological activity and immunochemical properties. Biokhimiia. 1988;53:61-8.
32. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6:903-18.
33. Rosenberg AS. Effect of protein aggregates: an immunologic perspective. The AAPS Journal. 2006; 8(3) Article 59 (http://www.aaps.org). Accessed 3 Dec 2011.
34. Cleland J, Powell M, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10:307-77.
35. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res. 2003;20:1903-7.
36. Schrier JA, Kenley RA, Williams R, Corcoran RJ, Kim Y, Northey RP, D'Augusta D, Hberty M. Degradation pathways for recombinant human macrophage colony-stimulating factor in aqueous solution. Pharm Res. 1993;10:933-44.
37. Kenley RA, Warne NW. Acid catalyzed peptide bond hydrolysis of recombinant human interleukin 11. Pharm Res. 1994;11:72-6.
38. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci. 2010;99:2582-97.
39. Tandon S, Horowitz PM. Detergent-assisted refolding of guanidinium chloride-denatured rhodanese - the effects of the concentration and type of detergent. J Biol Chem. 1987;262:4486-91.
40. Hassan MS, Lau RWM. Effect of particle shape on dry particle inhalation: study of flowability, aerosolization and deposition properties. AAPS PharmSciTech. 2009;10:1252-62.